- $125.62m
- -$28.41m
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
U.S. STOCKS ON THE MOVE-Cooper, US energy stocks, Vista Outdoor
Kinnate Bio rises after selling a cancer therapy to Pierre Fabre
Brief: Kinnate Biopharma Sells Its Investigational Pan-RAF Inhibitor to Pierre Fabre Laboratories
U.S. STOCKS ON THE MOVE-DT Midstream, Bio-Rad Labs, Copper miners
U.S. STOCKS ON THE MOVE-Super Micro Computer, Kinsale Capital, Kinnate Biopharma
Kinnate Biopharma rises as co to be acquired by XOMA Corp
Brief: Xoma Enters Into Agreement To Acquire Kinnate Biopharma
Brief: Kinnate Biopharma Inc. Enters Into Agreement To Be Acquired By Xoma Corporation
Brief: Kinnate Biopharma To Cut 56% Workforce
U.S. STOCKS ON THE MOVE-Thermo Fisher, Palo Alto, American Eagle Outfitters
U.S. STOCKS ON THE MOVE-Kinnate, Walt Disney, VF Corp
Brief: Kinnate BiopharmaBoard Got Letter From Funds Affiliated With Foresite Capital Management
Kinnate gains on potential deal to go private
Brief: Kinnate Biopharma Q3 Basic EPS USD -0.65